tiprankstipranks
Chugai Pharmaceutical Co Ltd (CHGCF)
OTHER OTC:CHGCF
Holding CHGCF?
Track your performance easily

Chugai Pharmaceutical Co (CHGCF) Stock Price & Analysis

16 Followers

CHGCF Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

5.11%0.08%91.08%
Insiders
0.08% Other Institutional Investors
91.08% Public Companies and
Individual Investors

CHGCF FAQ

What was Chugai Pharmaceutical Co Ltd’s price range in the past 12 months?
Chugai Pharmaceutical Co Ltd lowest stock price was $28.60 and its highest was $53.52 in the past 12 months.
    What is Chugai Pharmaceutical Co Ltd’s market cap?
    Currently, no data Available
    When is Chugai Pharmaceutical Co Ltd’s upcoming earnings report date?
    Chugai Pharmaceutical Co Ltd’s upcoming earnings report date is Jan 30, 2025 which is in 39 days.
      How were Chugai Pharmaceutical Co Ltd’s earnings last quarter?
      Chugai Pharmaceutical Co Ltd released its earnings results on Oct 25, 2024. The company reported $0.433 earnings per share for the quarter, beating the consensus estimate of $0.393 by $0.04.
        Is Chugai Pharmaceutical Co Ltd overvalued?
        According to Wall Street analysts Chugai Pharmaceutical Co Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Chugai Pharmaceutical Co Ltd pay dividends?
          Chugai Pharmaceutical Co Ltd pays a Annually dividend of $0.267 which represents an annual dividend yield of 1.28%. See more information on Chugai Pharmaceutical Co Ltd dividends here
            What is Chugai Pharmaceutical Co Ltd’s EPS estimate?
            Chugai Pharmaceutical Co Ltd’s EPS estimate is $0.38.
              How many shares outstanding does Chugai Pharmaceutical Co Ltd have?
              Chugai Pharmaceutical Co Ltd has 1,679,057,600 shares outstanding.
                What happened to Chugai Pharmaceutical Co Ltd’s price movement after its last earnings report?
                Chugai Pharmaceutical Co Ltd reported an EPS of $0.433 in its last earnings report, beating expectations of $0.393. Following the earnings report the stock price went down -0.438%.
                  Which hedge fund is a major shareholder of Chugai Pharmaceutical Co Ltd?
                  Currently, no hedge funds are holding shares in CHGCF
                  ---

                  Chugai Pharmaceutical Co Stock Smart Score

                  Company Description

                  Chugai Pharmaceutical Co Ltd

                  Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of the pharmaceuticals. Its operations are carried out through the following business divisions: Research, Development, Production, Marketing, Medical Affairs and Drug Safety. The Research division focuses its efforts on creating innovative drugs by using its competitive strengths that include proprietary antibody technologies and cutting-edge research resources. The Development division provides cross-functional lifecycle management system to deliver innovative medicines to patients as quickly as possible. The Production division provides a world-class safety and quality management systems. The Marketing division conducts patient-oriented marketing activities to help solve issues related to healthcare. The Medical Affairs division works to properly deliver the value of medicines based on global compliance standards. The Drug Safety provides safety management system includes expert safety evaluation as well as timely gathering and reporting of safety information. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.
                  ---

                  CHGCF Company Deck

                  ---

                  CHGCF Earnings Call

                  Q2 2024
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The earnings call highlighted significant progress in operating profit and overseas sales, particularly driven by Hemlibra and Actemra exports. However, the company faced challenges with revenue decline due to the absence of Ronapreve and domestic market pressures. Despite these challenges, the strong performance in new product launches and improved cost structure suggest a positive outlook.Read More>
                  ---

                  CHGCF Stock 12 Month Forecast

                  Average Price Target

                  $48.08
                  ▲(15.02% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"$29","42":"$42","55":"$55","35.5":"$35.5","48.5":"$48.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54.33217,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$54.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.35212,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.35</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,35.5,42,48.5,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.63,43.530166923076926,44.43033384615385,45.33050076923077,46.23066769230769,47.130834615384614,48.03100153846154,48.93116846153846,49.831335384615386,50.73150230769231,51.63166923076923,52.53183615384615,53.432003076923074,{"y":54.33217,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.63,43.049230769230775,43.46846153846154,43.88769230769231,44.30692307692308,44.72615384615385,45.145384615384614,45.56461538461539,45.98384615384615,46.403076923076924,46.82230769230769,47.24153846153846,47.66076923076923,{"y":48.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.63,42.30093230769231,41.97186461538462,41.64279692307692,41.31372923076923,40.98466153846154,40.65559384615385,40.32652615384615,39.997458461538464,39.66839076923077,39.33932307692308,39.010255384615384,38.68118769230769,{"y":38.35212,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.37,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":36.29,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.7,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":37.56,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":31.94,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":30.26,"date":1716508800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.36,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.58,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.64,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.93,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.47,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.22,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.63,"date":1733443200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Amgen
                  Gilead Sciences
                  Regeneron
                  Vertex Pharmaceuticals

                  Best Analysts Covering CHGCF

                  1 Year
                  Seiji WakaoJ.P. Morgan
                  1 Year Success Rate
                  1/2 ratings generated profit
                  50%
                  1 Year Average Return
                  +0.90%
                  reiterated a buy rating 19 days ago
                  Copying Seiji Wakao's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.90% per trade.
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis